Navigation Links
Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
Date:2/6/2013

d cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, the lengthy and uncertain regulatory approval process, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships.  Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable gene-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and Sangamo undertakes no duty to update such information except as required under applicable law.SELECTED CONSOLIDATED FINANCIAL DATA(in thousands, except per share data)(unaudited) Three Months Ended Twelve Months Ended December 31,  December 31, 2012201120122011Statement of Operations Data:Revenues:Collaboration agreements

$
8,520$
3,234$  18,186$
,110Research grants

4111,5143,4694,209Total revenues

8,9314,74821,65510,319Operating expenses:Research and development

9,2817,87831,70932,098General and administrative

3,0193,23512,14414,042Total operating expenses

12,30011,11343,85346,140Loss from operations

(3,369)(6,365)(22,198)(35,821)Interest and other income (expense), net

(109)6(66)71Net loss

$
(3,478)$
(6,359)$(22,264)$(35,750)Basic and diluted net loss per common share

$
(0.07)$
(0.12)$<
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
2. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
3. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
5. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
6. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
7. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
8. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
9. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
10. Pressure BioSciences Partners with Constant Systems to Significantly Expand Product Offerings and International Distribution
11. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Cardiac Dimensions ® , Inc. ... the TITAN II clinical trial of its enhanced ... improvements in mitral regurgitation, functional improvement, quality of ... and efficacy data, which was consistent with previous ... at the 26 th annual Transcatheter Cardiovascular ...
(Date:9/17/2014)... , Sept. 17, 2014 Isis Pharmaceuticals, ... it has earned a $4 million milestone payment ... associated with the initiation of a Phase 3 ... resistant (MDR), gram-negative bacterial infections.  The Phase 3 ... evaluate the efficacy and safety of plazomicin compared ...
(Date:9/17/2014)... ALTO, Calif. , Sept. 17, 2014  Neuraltus ... the Company,s Phase 2 clinical program of NP001 for ... Lou Gehrig,s disease) are being highlighted today in ... the ALS Research Group , being held in ... to a  post hoc  analysis, administration of a high ...
Breaking Medicine Technology:Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
(Date:9/17/2014)... DMG Productions announces the upcoming airing ... broadcast on Wednesday, September 24, 2014 at 7:30 ... episode, Innovations will go behind the scenes to ... each client the opportunity to achieve the highest ... principles of Care, Compassion, and Commitment. , Audiences ...
(Date:9/17/2014)... 2014 Kristen Yarker, MSc, RD recently announced ... children 9 months to 2 years old who are seeking ... picky eaters from developing by encouraging healthy eating habits from ... to 2 years): How to Transition From Baby Food to ... the Nutrition They Need)” is a new online seminar based ...
(Date:9/17/2014)... Wailea, Maui, HI (PRWEB) September 17, 2014 ... has announced the eighth annual Wailea Tennis Fantasy ... 19-23, 2014 at Maui’s prestigious Wailea Tennis Club, with ... ranked Lindsay Davenport returning to Wailea, Maui for her ... world-class instruction and match play with Davenport, recently inducted ...
(Date:9/17/2014)... In a new video released for ... expert on the condition known as PPP, demonstrates a proven ... or PPP, is a condition that affects mostly uncircumcised men ... affected as well. The condition is characterized by small bumps ... is not a sexually transmitted disease and generally has no ...
(Date:9/17/2014)... 17, 2014 Request A Test , ... is offering 10% off drug testing through the ... drug tests, including those ordered by employers for workplace or ... of this discount by using promo code DRUG10 when placing ... positives on workplace drug testing, especially for marijuana or THC. ...
Breaking Medicine News(10 mins):Health News:Innovations to Explore Substance Abuse and Mental Health in Upcoming Episode Airing Wednesday, September 24, 2014 via Discovery Channel. 2Health News:Nutritionist Kristen Yarker Offers Parents a Fresh Approach to Prevent Picky Eaters in New Online Seminar 2Health News:Nutritionist Kristen Yarker Offers Parents a Fresh Approach to Prevent Picky Eaters in New Online Seminar 3Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 2Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 3Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3Health News:Request A Test Can Save You 10% on Drug Testing 2Health News:Request A Test Can Save You 10% on Drug Testing 3
... Center have found a new method for identifying suspect ... common acute infections in children. ,Traditionally, researchers ... down the virus or bacteria causing it. But that ... not be present in the blood or other easily ...
... from University of Missouri, Columbia indicates that the masculine tendencies ... been assumed all along that such tendencies were the barriers ... this issue. ,Generally it has been said that ... quality is said to aid in their recovery in traumatic ...
... major Ranbaxy Laboratories Ltd says it has obtained tentative approval ... market a drug for insomnia. ,The US unit ... Drugs, US FDA, has determined the Ranbaxy formulations of Zolpidem ... therapeutic effect as that of Ambien tablets of Sanofi Aventis ...
... Health Services called Frontpoint Systems (http://www.frontpointsystems.co.uk /weblog) has ... Royal College of Obstetricians & Gynaecologists indicating a ... ,The site highlights what is wrong ... in the UK has published a letter from ...
... of Virginia Health System suggests that composition of plaque deposits ... a stroke. ,Published in the March edition of ... deposits in the carotid arteries of 102 patients treated at ... likely to have a stroke, physicians may want to take ...
... the risk of death among children aged 12 to 48 ... conducted by researchers at the Johns Hopkins Bloomberg School of ... in mortality among children 1 to11 months of age. The ... The Lancet. ,Zinc is one of the ...
Cached Medicine News:Health News:‘Fingerprints’ to Track Common Infections in Childr 2Health News:‘Fingerprints’ to Track Common Infections in Childr 3Health News:More Evidence of Racial Discrimination in the NHS 2Health News:Calcium in Arterial Plaque is a Good Indicator for Risk of Stroke 2Health News:Zinc Supplements Enhance Immunity in Children 2
Tennant straight tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
McPherson curved tying forceps is long has curved shafts with tying platform 4 mm, serrated handle and polished finish. Overall length 110 mm....
McPherson straight tying forceps have straight shafts, tying platforms 4 mm, serrated handle, polished finish, overall length 85 mm....
Medicine Products: